Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Eltanexor

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Karyopharm reports interim data from eltanexor Phase I/II study
    Karyopharm reports interim data from eltanexor Phase I/II study

    04 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/karyopharm-interim-eltanexor/

    CLINICAL TRIALS ARENA
    04 May 2023
    Share Share
    Karyopharm Announces Presentation Data from pH 2 Study of Single-Agent Eltanexor
    Karyopharm Announces Presentation Data from pH 2 Study of Single-Agent Eltanexor

    03 May 2023

    // BUSINESSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-presentation-of-interim-data-from-phase-2-study-of-single-agent-eltanexor-in-relapsedrefractory-rr-higher-risk-myelodysplastic-neoplasms-mds-at-17th-international-congress-on-mds-301814640.html

    BUSINESSWIRE
    03 May 2023
    Share Share
    Karyopharm Receives ODD from FDA for Eltanexor in Myelodysplastic Syndromes
    Karyopharm Receives ODD from FDA for Eltanexor in Myelodysplastic Syndromes

    24 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-receives-orphan-drug-designation-from-fda-for-eltanexor-for-the-treatment-of-myelodysplastic-syndromes-301466251.html

    PRNEWSWIRE
    24 Jan 2022
    Share Share
    Karyopharm Announces Dosing of First Patient in a Phase 2 Stud
    Karyopharm Announces Dosing of First Patient in a Phase 2 Stud

    21 Oct 2021

    // Brian Park PRESS RELEASE

    https://investors.karyopharm.com/2021-10-21-Karyopharm-Announces-Dosing-of-First-Patient-in-a-Phase-2-Study-Investigating-Oral-Eltanexor-in-HMA-Refractory-Myelodysplastic-Syndrome

    Brian Park PRESS RELEASE
    21 Oct 2021
    Share Share
    Karyopharm Therapeutics Announces Updated Data of Eltanexor
    Karyopharm Therapeutics Announces Updated Data of Eltanexor

    09 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/antengenes-partner-karyopharm-therapeutics-announces-updated-data-of-eltanexor-in-patients-with-hypomethylating-agent-refractory-mds-301308428.html

    PRNEWSWIRE
    09 Jun 2021
    Share Share
    Approval of Ph I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation
    Approval of Ph I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation

    25 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/approval-of-phase-iii-clinical-trial-of-atg-016-eltanexor-a-second-generation-selective-inhibitor-of-nuclear-export-sine-in-mainland-china-for-the-treatment-of-myelodysplastic-syndrome-301180877.html

    PRNEWSWIRE
    25 Nov 2020
    Share Share